|
1
|
Chan S: A review of selective estrogen
receptor modulators in the treatment of breast and endometrial
cancer. Semin Oncol. 29(Suppl 11): 129–133. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ito K, Utsunomiya H, Yaegashi N and Sasano
H: Biological roles of estrogen and progesterone in human
endometrial carcinoma - new developments in potential endocrine
therapy for endometrial cancer. Endocr J. 54:667–679. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bochkareva NV, Kolomiets LA, Kondakova IV,
Stukanov SL, Starova AB and Agarkova LA: Enzymes of estrogen
metabolism in endometrial cancer. Bull Exp Biol Med. 141:240–242.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Y, Huang Q, Chen Q, Lin Y, Sun X,
Zhang H, Zhu M and Dong S: The inflammation and estrogen metabolism
impacts of polychlorinated biphenyls on endometrial cancer cells.
Toxicol In Vitro. 29:308–313. 2015. View Article : Google Scholar
|
|
6
|
Williams-Brown MY, Salih SM, Xu X,
Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastia CR and Salama SA:
The effect of tamoxifen and raloxifene on estrogen metabolism and
endometrial cancer risk. J Steroid Biochem Mol Biol. 126:78–86.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Z, Zhou D, Lai Y, Liu Y, Tao X, Wang
Q, Zhao G, Gu H, Liao H, Zhu Y, et al: Estrogen induces endometrial
cancer cell proliferation and invasion by regulating the fat mass
and obesity-associated gene via PI3K/AKT and MAPK signaling
pathways. Cancer Lett. 319:89–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
da Cunha PA, de Carlos Back LK, Sereia AF,
Kubelka C, Ribeiro MC, Fernandes BL and de Souza IR: Interaction
between obesity-related genes, FTO and MC4R, associated to an
increase of breast cancer risk. Mol Biol Rep. 40:6657–6664. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gaudet MM, Yang HP, Bosquet JG, Healey CS,
Ahmed S, Dunning AM, Easton DF, Spurdle AB, Ferguson K, O'Mara T,
et al: No association between FTO or HHEX and endometrial cancer
risk. Cancer Epidemiol Biomarkers Prev. 19:2106–2109. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hernández-Caballero ME and Sierra-Ramírez
JA: Single nucleotide polymorphisms of the FTO gene and cancer
risk: An overview. Mol Biol Rep. 42:699–704. 2015. View Article : Google Scholar
|
|
11
|
Kaklamani V, Yi N, Sadim M, Siziopikou K,
Zhang K, Xu Y, Tofilon S, Agarwal S, Pasche B and Mantzoros C: The
role of the fat mass and obesity associated gene (FTO) in breast
cancer risk. BMC Med Genet. 12:522011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lewis SJ, Murad A, Chen L, Davey Smith G,
Donovan J, Palmer T, Hamdy F, Neal D, Lane JA, Davis M, et al:
Associations between an obesity related genetic variant (FTO
rs9939609) and prostate cancer risk. PLoS One. 5:e134852010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lurie G, Gaudet MM, Spurdle AB, Carney ME,
Wilkens LR, Yang HP, Weiss NS, Webb PM, Thompson PJ, Terada K;
Australian National Endometrial Cancer Study Group; et al:
Epidemiology of Endometrial Cancer Consortium (E2C2): The
obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313
and endometrial cancer risk in non-Hispanic white women. PLoS One.
6:e167562011. View Article : Google Scholar
|
|
14
|
Fischer J, Koch L, Emmerling C, Vierkotten
J, Peters T, Brüning JC and Rüther U: Inactivation of the Fto gene
protects from obesity. Nature. 458:894–898. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wong M: A critical review of mTOR
inhibitors and epilepsy: From basic science to clinical trials.
Expert Rev Neurother. 13:657–669. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu J and Tian D: Hematologic toxicities
associated with mTOR inhibitors temsirolimus and everolimus in
cancer patients: A systematic review and meta-analysis. Curr Med
Res Opin. 30:67–74. 2014. View Article : Google Scholar
|
|
17
|
Atefi M, von Euw E, Attar N, Ng C, Chu C,
Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, et al:
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by
co-targeting the AKT/mTOR pathway. PLoS One. 6:e289732011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jazirehi AR, Wenn PB and Damavand M:
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR
signaling module in melanoma therapy. Am J Cancer Res. 2:178–191.
2012.PubMed/NCBI
|
|
19
|
Pópulo H, Soares P and Lopes JM: Insights
into melanoma: Targeting the mTOR pathway for therapeutics. Expert
Opin Ther Targets. 16:689–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bae SY, Kim GD, Jeon JE, Shin J and Lee
SK: Anti-proliferative effect of (19Z)-halichondramide, a novel
marine macrolide isolated from the sponge Chondrosia corticata, is
associated with G2/M cell cycle arrest and suppression of mTOR
signaling in human lung cancer cells. Toxicol In Vitro. 27:694–699.
2013. View Article : Google Scholar
|
|
21
|
Dong LX, Sun LL, Zhang X, Pan L, Lian LJ,
Chen Z and Zhong DS: Negative regulation of mTOR activity by
LKB1-AMPK signaling in non-small cell lung cancer cells. Acta
Pharmacol Sin. 34:314–318. 2013. View Article : Google Scholar
|
|
22
|
Papadimitrakopoulou V: Development of
PI3K/AKT/mTOR pathway inhibitors and their application in
personalized therapy for non-small-cell lung cancer. J Thorac
Oncol. 7:1315–1326. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bradford LS, Rauh-Hain A, Clark RM,
Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R
and Rueda BR: Assessing the efficacy of targeting the
phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in
endometrial cancer. Gynecol Oncol. 133:346–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen J, Zhao KN, Li R, Shao R and Chen C:
Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and
mTOR in endometrial cancer. Curr Med Chem. 21:3070–3080. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng H, Liu P, Zhang F, Xu E, Symonds L,
Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, et al: A
genetic mouse model of invasive endometrial cancer driven by
concurrent loss of Pten and Lkb1 Is highly responsive to mTOR
inhibition. Cancer Res. 74:15–23. 2014. View Article : Google Scholar :
|
|
26
|
Myers AP: New strategies in endometrial
cancer: Targeting the PI3K/mTOR pathway - the devil is in the
details. Clin Cancer Res. 19:5264–5274. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pavlidou A and Vlahos NF: Molecular
alterations of PI3K/Akt/mTOR pathway: A therapeutic target in
endometrial cancer. ScientificWorldJournal. 2014:7097362014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Z, Dong L, Sui L, Yang Y, Liu X, Yu
Y, Zhu Y and Feng Y: Metformin reverses progestin resistance in
endometrial cancer cells by downregulating GloI expression. Int J
Gynecol Cancer. 21:213–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chao A, Lin CY, Tsai CL, Hsueh S, Lin YY,
Lin CT, Chou HH, Wang TH, Lai CH and Wang HS: Estrogen stimulates
the proliferation of human endometrial cancer cells by stabilizing
nucleophosmin/B23 (NPM/B23). J Mol Med Berl. 91:249–259. 2013.
View Article : Google Scholar
|
|
30
|
Thorne AM, Jackson TA, Willis VC and
Bradford AP: Protein kinase Cα modulates
estrogen-receptor-dependent transcription and proliferation in
endometrial cancer cells. Obstet Gynecol Int. 2013:5374792013.
View Article : Google Scholar
|
|
31
|
Zhou C, Steplowski TA, Dickens HK, Malloy
KM, Gehrig PA, Boggess JF and Bae-Jump VL: Estrogen induction of
telomerase activity through regulation of the mitogen-activated
protein kinase (MAPK) dependent pathway in human endometrial cancer
cells. PLoS One. 8:e557302013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hou X, Zhao M, Wang T and Zhang G:
Upregulation of estrogen receptor mediates migration, invasion and
proliferation of endometrial carcinoma cells by regulating the
PI3K/AKT/mTOR pathway. Oncol Rep. 31:1175–1182. 2014.
|
